AIDX
Trending >

CURA stock is a buy, Roth says

CURA

Looking for a pot stock that distinguishes itself from the pack? Look no further than Curaleaf Holdings (Curaleaf Holdings Stock Quote, Chart, News, Analysts, Financials TSX:CURA).

That’s the opinion of Roth MKM Managing Director Scott Fortune, who In a research update to clients January 18 maintained his “Buy” rating and price target of $7.00 on CURA.

The analyst said there a key things that set CURA apart.

“CURA remains the largest cannabis operator and is differentiated from MSO peers with its well positioned international exposure and TSX listing,” the analyst wrote. “We believe the company is nearing an inflection point toward higher top-line growth and margin expansion after prioritizing international infrastructure ahead of German adult-use legalization. Management maintains its mid-single-digit revenue growth outlook for 2024, with gross margins approaching 50% and EBITDA margins reaching 25%. We expect outsized 2025 growth off the back of international growth, CURA’s key differentiator.”

Fortune thinks CURA will post EBITDA of $335.5-million on revenue of $1.40-billion in fiscal 2024. He expects those numbers will improve to EBITDA of $377.8-million on a topline of $1.55-billion the following year.

“We believe CURA is best positioned among the MSOs to benefit from international markets ramping, while maintaining a robust state presence and wholesale infrastructure stateside to capitalize on new markets legalizing, the analyst concluded.

About The Author /

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
insta twitter facebook

Comment